MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake is supported by unusually strong clinical differentiation for SLK, with Week 52 hidradenitis suppurativa data showing 67.2% HiSCR75 and 33.1% HiSCR100, alongside durable patient-reported benefits and no new safety signals in IZAR-1. The Week 16 psoriatic arthritis readout was also compelling, with 42.1% ACR50, 66.5% ACR20, 41.2% MDA, and 61% PASI90 in patients with skin involvement, supporting a credible path to broad use across inflammatory skin and joint diseases. Fundamentally, the bullish view is reinforced by a timely BLA submission, roughly $230M in gross proceeds that may fund commercialization with limited dilution, and a valuation that appears modest versus larger peers despite SLK’s earlier-stage but high-conviction profile.

MoonLake is challenged by a highly uncertain valuation profile, as its DCF assumptions swing materially from a $4.4B firm value under a 12% discount rate to $3.9B under a 15% rate, underscoring how sensitive the company is to execution and financing conditions. The thesis is weakened by the dependence on SLK achieving only probabilistic approval in HS, PsA, and axSpA, while pivotal-trial delays, regulatory setbacks, and failure to demonstrate compelling efficacy could quickly erode expected upside. In addition, competitive pressure, slower-than-projected uptake, partnership risk, and the possibility of long-term dilution against ~87M to ~88M fully diluted shares as of mid-2027 support a cautious fundamental outlook.